These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

368 related items for PubMed ID: 10642802

  • 1. High-dose busulfan/melphalan as conditioning for autologous PBPC transplantation in pediatric patients with solid tumors.
    Diaz MA, Vicent MG, Madero L.
    Bone Marrow Transplant; 1999 Dec; 24(11):1157-9. PubMed ID: 10642802
    [Abstract] [Full Text] [Related]

  • 2. High-dose busulfan and melphalan as conditioning regimen for autologous peripheral blood progenitor cell transplantation in high-risk neuroblastoma patients.
    Molina B, Alonso L, Gonzalez-Vicent M, Andion M, Hernandez C, Lassaletta A, Cormenzana M, Lopez-Ibor B, Villa M, Molina J, Diaz MA.
    Pediatr Hematol Oncol; 2011 Mar; 28(2):115-23. PubMed ID: 21299340
    [Abstract] [Full Text] [Related]

  • 3. High-dose busulphan/melphalan with autologous stem cell rescue in Ewing's sarcoma.
    Atra A, Whelan JS, Calvagna V, Shankar AG, Ashley S, Shepherd V, Souhami RL, Pinkerton CR.
    Bone Marrow Transplant; 1997 Nov; 20(10):843-6. PubMed ID: 9404924
    [Abstract] [Full Text] [Related]

  • 4. Megachemotherapy followed by autologous stem cell transplantation in children with Ewing's sarcoma.
    Drabko K, Zawitkowska-Klaczynska J, Wojcik B, Choma M, Zaucha-Prazmo A, Kowalczyk J, Gorczynska E, Toporski J, Kałwak K, Turkiewicz D, Chybicka A.
    Pediatr Transplant; 2005 Oct; 9(5):618-21. PubMed ID: 16176419
    [Abstract] [Full Text] [Related]

  • 5. High-dose sequential chemotherapy and autologous stem cell reinfusion in advanced pediatric solid tumors.
    Chan KW, Petropoulos D, Choroszy M, Herzog C, Jaffe N, Ater J, Korbling M.
    Bone Marrow Transplant; 1997 Dec; 20(12):1039-43. PubMed ID: 9466276
    [Abstract] [Full Text] [Related]

  • 6. High-dose busulfan and melphalan as conditioning regimen for autologous peripheral blood progenitor cell transplantation in high-risk ewing sarcoma patients: a long-term follow-up single-center study.
    Diaz MA, Lassaletta A, Perez A, Sevilla J, Madero L, Gonzalez-Vicent M.
    Pediatr Hematol Oncol; 2010 May; 27(4):272-82. PubMed ID: 20426518
    [Abstract] [Full Text] [Related]

  • 7. Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Société Française des Cancers de l'Enfant.
    Oberlin O, Rey A, Desfachelles AS, Philip T, Plantaz D, Schmitt C, Plouvier E, Lejars O, Rubie H, Terrier P, Michon J, Société Française des Cancers de l'Enfant.
    J Clin Oncol; 2006 Aug 20; 24(24):3997-4002. PubMed ID: 16921053
    [Abstract] [Full Text] [Related]

  • 8. High-dose melphalan with autologous hematopoietic stem cell transplantation for acute myeloid leukemia: results of a retrospective analysis of the Italian Pediatric Group for Bone Marrow Transplantation.
    Cesaro S, Meloni G, Messina C, Pillon M, Proglia A, Lanino E, Caniggia M, Bagnulo S, Pession A, Locatelli F, Italian Pediatric Group for Bone Marrow Transplantation.
    Bone Marrow Transplant; 2001 Jul 20; 28(2):131-6. PubMed ID: 11509930
    [Abstract] [Full Text] [Related]

  • 9. Phase I study of high-dose busulfan, melphalan and thiotepa with autologous stem cell support in patients with refractory malignancies.
    Weaver CH, Bensinger WI, Appelbaum FR, Lilleby K, Sandmaier B, Brunvand M, Rowley S, Petersdorf S, Rivkin S, Gooley T.
    Bone Marrow Transplant; 1994 Nov 20; 14(5):813-9. PubMed ID: 7889015
    [Abstract] [Full Text] [Related]

  • 10. Myeloablative chemotherapy with autologous peripheral blood stem cell transplantation in patients with poor-prognosis solid tumors - Bulgarian experience.
    Avramova B, Jordanova M, Michailov G, Konstantinov D, Christosova I, Bobev D.
    J BUON; 2006 Nov 20; 11(4):433-8. PubMed ID: 17309174
    [Abstract] [Full Text] [Related]

  • 11. [High-dose chemotherapy with autologous peripheral blood stem cell transplantation (PBSCT) for refractory bone and soft tissue sarcomas].
    Yonemoto T, Tatezaki S, Ishii T, Satoh T.
    Gan To Kagaku Ryoho; 1999 Sep 20; 26(10):1431-5. PubMed ID: 10500530
    [Abstract] [Full Text] [Related]

  • 12. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
    Kröger N, Zabelina T, Sonnenberg S, Krüger W, Renges H, Stute N, Finkenstein F, Mayer U, Holstein K, Fiedler W, Colberg H, Sonnen R, Kuse R, Braumann D, Metzner B, del Valle F, Erttmann R, Kabisch H, Zander AR.
    Bone Marrow Transplant; 2000 Oct 20; 26(7):711-6. PubMed ID: 11042650
    [Abstract] [Full Text] [Related]

  • 13. Double-conditioning regimens consisting of thiotepa, melphalan and busulfan with stem cell rescue for the treatment of pediatric solid tumors.
    Hara J, Osugi Y, Ohta H, Matsuda Y, Nakanishi K, Takai K, Fujisaki H, Tokimasa S, Fukuzawa M, Okada A, Okada S.
    Bone Marrow Transplant; 1998 Jul 20; 22(1):7-12. PubMed ID: 9678789
    [Abstract] [Full Text] [Related]

  • 14. Autologous stem cell transplantation for high-risk pediatric solid tumors.
    Perentesis J, Katsanis E, DeFor T, Neglia J, Ramsay N.
    Bone Marrow Transplant; 1999 Sep 20; 24(6):609-15. PubMed ID: 10490725
    [Abstract] [Full Text] [Related]

  • 15. High-dose melphalan +/- total body irradiation and autologous hematopoietic stem cell rescue for adult patients with Ewing's sarcoma or peripheral neuroectodermal tumor.
    Stewart DA, Gyonyor E, Paterson AH, Arthur K, Temple W, Schachar NS, Klassen J, Brown C, Russell JA.
    Bone Marrow Transplant; 1996 Aug 20; 18(2):315-8. PubMed ID: 8864440
    [Abstract] [Full Text] [Related]

  • 16. Absence of veno-occlussive disease in a cohort of multiple myeloma patients undergoing autologous stem cell transplantation with targeted busulfan dosage.
    Clopés A, Sureda A, Sierra J, Queraltó JM, Broto A, Farré R, Moreno E, Brunet S, Martino R, Mangues MA.
    Eur J Haematol; 2006 Jul 20; 77(1):1-6. PubMed ID: 16573745
    [Abstract] [Full Text] [Related]

  • 17. Haploidentical stem cell transplantation in patients with pediatric solid tumors: preliminary results of a pilot study and analysis of graft versus tumor effects.
    Lang P, Pfeiffer M, Müller I, Schumm M, Ebinger M, Koscielniak E, Feuchtinger T, Föll J, Martin D, Handgretinger R.
    Klin Padiatr; 2006 Jul 20; 218(6):321-6. PubMed ID: 17080334
    [Abstract] [Full Text] [Related]

  • 18. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.
    Carreras E, Rosiñol L, Terol MJ, Alegre A, de Arriba F, García-Laraña J, Bello JL, García R, León A, Martínez R, Peñarrubia MJ, Poderós C, Ribas P, Ribera JM, San Miguel J, Bladé J, Lahuerta JJ, Spanish Myeloma Group/PETHEMA.
    Biol Blood Marrow Transplant; 2007 Dec 20; 13(12):1448-54. PubMed ID: 18022574
    [Abstract] [Full Text] [Related]

  • 19. Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin.
    Bornhäuser M, Thiede C, Schuler U, Platzbecker U, Freiberg-Richter J, Helwig A, Plettig R, Röllig C, Naumann R, Kroschinsky F, Neubauer A, Ehninger G.
    Bone Marrow Transplant; 2000 Jul 20; 26(2):119-25. PubMed ID: 10918420
    [Abstract] [Full Text] [Related]

  • 20. Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies.
    Small TN, Young JW, Castro-Malaspina H, Prockop S, Wilton A, Heller G, Boulad F, Chiu M, Hsu K, Jakubowski A, Kernan NA, Perales MA, O'Reilly RJ, Papadopoulos EB.
    Biol Blood Marrow Transplant; 2007 Feb 20; 13(2):235-44. PubMed ID: 17241929
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.